No article notes available at this time.
• Angiosarcoma is often assumed to behave differently from other STS subtypes, but this pooled analysis shows similar response and survival with standard anthracycline-based chemotherapy — supporting its use as first-line treatment rather than defaulting to alternative regimens based on histology alone. • The finding that doxorubicin plus ifosfamide improved PFS and OS compared to single-agent anthracycline gives trainees evidence to weigh when discussing combination versus monotherapy in the metastatic/advanced setting, balancing efficacy against toxicity. • The reported response rates and survival figures offer a historical benchmark for angiosarcoma outcomes, useful when interpreting newer trials or targeted therapy studies in this rare subtype.
No article notes available at this time.
• Angiosarcoma is often assumed to behave differently from other STS subtypes, but this pooled analysis shows similar response and survival with standard anthracycline-based chemotherapy — supporting its use as first-line treatment rather than defaulting to alternative regimens based on histology alone. • The finding that doxorubicin plus ifosfamide improved PFS and OS compared to single-agent anthracycline gives trainees evidence to weigh when discussing combination versus monotherapy in the metastatic/advanced setting, balancing efficacy against toxicity. • The reported response rates and survival figures offer a historical benchmark for angiosarcoma outcomes, useful when interpreting newer trials or targeted therapy studies in this rare subtype.